Pharmaceuticals

Peptide And Oligonucleotide CDMO Market Forecast: What to Expect by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Peptide And Oligonucleotide CDMO Market From 2025 To 2034?

The peptide and oligonucleotide cdmo market has experienced significant expansion recently. Projections indicate its size will increase from $2.16 billion in 2024 to $2.42 billion in 2025, showing a compound annual growth rate (CAGR) of 11.8%. Historically, this expansion is a result of several factors, including an escalating need for therapeutic agents, innovations in synthesis and manufacturing processes, the emergence of personalized medicine, evolving regulatory frameworks, and a heightened emphasis on antiviral peptides and mRNA vaccines, which underscores the role of oligonucleotides in vaccine advancement.

The market for peptide and oligonucleotide CDMO services is projected to experience swift expansion over the coming years. By 2029, this market is anticipated to reach $3.69 billion, exhibiting a compound annual growth rate (CAGR) of 11.2%. This growth throughout the forecast period is driven by factors such as the rising need for personalized medicine, continuous advancements in biotechnology, a broader range of applications, a surge in outsourcing activities, and the increasing prevalence of chronic illnesses. Key trends expected during the same period encompass tailored therapies, ongoing technological improvements, hurdles in quality control, worldwide market expansion, and enhanced partnerships among biopharmaceutical entities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Are The Top Growth Drivers Impacting The Peptide And Oligonucleotide CDMO Market Outlook?

The expanded use of personalized medicine is anticipated to fuel expansion within the peptide and oligonucleotide CDMO markets. This healthcare methodology involves customizing medical choices and therapies based on unique individual traits, including genetics, environmental factors, and lifestyle. Its increasing prevalence stems from multiple elements like progress in genomic technologies, enhanced comprehension of disease processes at a molecular scale, and a need for more potent and precise treatments specifically designed for patients’ genetic profiles and health backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in personalized medicine as they produce bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. A case in point is that in February 2024, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) sanctioned 16 novel personalized therapies for patients with rare diseases, an increase from 6 in 2022, as reported by the Personalized Medicine Coalition, a UK-based group advocating for personalized medicine’s adoption. Consequently, the expanding embrace of personalized medicine is stimulating growth in the peptide and oligonucleotide CDMO market.

What Are The Major Segment Categories Driving The Peptide And Oligonucleotide CDMO Market Growth?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Are The Major Trends Driving The Growth Of The Peptide And Oligonucleotide CDMO Market?

Leading companies in the peptide and oligonucleotide CDMO market are prioritizing the formation of strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market presence. Peptide development and production partnerships involve collaborative agreements between two organizations focused on creating and manufacturing peptide-based therapeutics. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The collaboration is focused on jointly investigating the development of suitable peptide candidates with the goal of achieving more sustainable production of peptide-based APIs.

Which Industry Leaders Are Driving Innovation Across The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2025, By The Business Research Company

Biologics Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795